Find Novel Oncology Drugs in Clinical Development in UNITED STATES

Lead Product(s): GDC-0570

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Ningbo NewBay Medical Technology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 27, 2020

Details:

Ningbo NewBay Medical Technology has been granted the exclusive global rights to further develop and commercialize GDC-0570.

Lead Product(s): SNP-7/8a

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 15, 2020

Details:

The groundbreaking peptide-based personalized cancer vaccine was shown to more efficiently induce T-cell responses against tumor neoantigens compared to traditional vaccines.

Lead Product(s): T cell based therapy

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Astellas Pharma

Deal Size: $897.5 million Upfront Cash: $50.0 million

Deal Type: Agreement January 14, 2020

Details:

Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Alta Partners

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 10, 2020

Details:

Financing will used to discover and develop new small molecule therapies targeting acquired resistance in oncology.

Lead Product(s): Paclitaxel

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Series A Financing January 10, 2020

Details:

The funds raised will be used to further the development of its TYN-21 program, a novel, proprietary formulation of paclitaxel

Lead Product(s): Polypeptides

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Roche

Deal Size: $1,540.0 million Upfront Cash: $40.0 million

Deal Type: Licensing Agreement January 10, 2020

Details:

This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.

Lead Product(s): Centyrins

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Ionis Pharmaceuticals, Inc

Deal Size: $1,400.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 09, 2020

Details:

As per the agreement, the two companies have agreed to jointly work towards advancing a defined number of ASO-Centyrin drug conjugates.

Lead Product(s): DKN-01,tislelizumab

Therapeutic Area: Oncology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: BeiGene

Deal Size: $162.0 million Upfront Cash: $3.0 million

Deal Type: Licensing Agreement January 03, 2020

Details:

Under the terms and condition of the agreement, BeiGene is granted option to develop and commercialize Leap's DKN-01 in the Asia Pacific Region, excluding Japan.